Loading…
A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age
Background To improve outcome and overall survival (OS) in high‐risk neuroblastoma, NB96 induction therapy was intensified using sequential high‐dose chemotherapy and autologous stem cell rescue. Procedure Twenty children were included in this pilot study undertaken at seven reference centers in Fra...
Saved in:
Published in: | Pediatric blood & cancer 2011-12, Vol.57 (6), p.965-971 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713 |
---|---|
cites | cdi_FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713 |
container_end_page | 971 |
container_issue | 6 |
container_start_page | 965 |
container_title | Pediatric blood & cancer |
container_volume | 57 |
creator | Monnereau-Laborde, Sylvie Munzer, Caroline Valteau-Couanet, Dominique Ansoborlo, Sophie Coze, Carole Chastagner, Pascal Rubie, Hervé Demeocq, François Stephan, Jean-Louis Hartmann, Olivier Perel, Yves |
description | Background
To improve outcome and overall survival (OS) in high‐risk neuroblastoma, NB96 induction therapy was intensified using sequential high‐dose chemotherapy and autologous stem cell rescue.
Procedure
Twenty children were included in this pilot study undertaken at seven reference centers in France, between May 1995 and October 1996. Induction began with one cycle of conventional chemotherapy followed by six sequential cycles of high‐dose chemotherapy comprising two cycles of etoposide 800 mg/m2/day over 3 days, two cycles of cyclophosphamide 2,000 mg/m2/day over 3 days, and two cycles of carboplatin 400 mg/m2/day over 5 days, followed by stem cell rescue.
Results
Thirteen patients (13/20) received this induction with acceptable toxicity and adequate stem cell harvest. Of these, nine (9/13) underwent surgery according to the protocol, while one patient was given a consolidation regimen prior to surgery. No toxic death was recorded. At the end of induction, complete remission was achieved in 10 cases (50%), with six still alive in July 2009. The 5‐year event‐free survival and OS were 35 ± 11% and 40 ± 11%, respectively.
Conclusion
NB96 therapy is feasible and tolerated without lethal toxicity. Nevertheless, given the small sample size and absence of randomization in our study, the effectiveness of this strategy based on metastasis complete response rates and long‐term outcome was not superior to other intensive chemotherapy regimens. Pediatr Blood Cancer 2011; 57: 965–971. © 2011 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/pbc.23232 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1367482593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1367482593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhiMEoqVw4AWQj-0hbRzbsXNsF1iQqsKhFG6WY082pokd7KSwvBVviJd094bm4JH8zSfN_Fn2GhfnuCjKi7HR5yVJ9SQ7xoyynBWYPz30RX2UvYjxe0Krgonn2VGJOaVU4OPszyUyPkJu3QQu2gdAahyDV7pDpzdXdXWGWh-QdWbWk_UOTR0ENW7RPNne_rZugyL8mMFNVvWos5su3-mQ7mDwe1Y5g-IEA9LQ9yhA1DMk5YIHG--Rgzn4pldx8oPafenO9iaAQ_4BAsJoCyog3yK1gZfZs1b1EV49vifZl_fvblcf8utP64-ry-tck5qVeQulogqgEaLERhBaVoK2AtdNbbhuoOC1IDUF0QIWDSdG0bYyQjQtI4ZzTE6y08WbzpE2jJMcbNxtoBz4OUpMKk5FyWqS0LMF1cHHGKCVY7CDCluJC7lLSKaE5L-EEvvmUTs3A5gDuY8kARcL8NP2sP2_SX6-Wu2V-TJh05V_HSZUuJcVJ5zJrzdrecdu19_eiju5In8BCyOsdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367482593</pqid></control><display><type>article</type><title>A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Monnereau-Laborde, Sylvie ; Munzer, Caroline ; Valteau-Couanet, Dominique ; Ansoborlo, Sophie ; Coze, Carole ; Chastagner, Pascal ; Rubie, Hervé ; Demeocq, François ; Stephan, Jean-Louis ; Hartmann, Olivier ; Perel, Yves</creator><creatorcontrib>Monnereau-Laborde, Sylvie ; Munzer, Caroline ; Valteau-Couanet, Dominique ; Ansoborlo, Sophie ; Coze, Carole ; Chastagner, Pascal ; Rubie, Hervé ; Demeocq, François ; Stephan, Jean-Louis ; Hartmann, Olivier ; Perel, Yves</creatorcontrib><description>Background
To improve outcome and overall survival (OS) in high‐risk neuroblastoma, NB96 induction therapy was intensified using sequential high‐dose chemotherapy and autologous stem cell rescue.
Procedure
Twenty children were included in this pilot study undertaken at seven reference centers in France, between May 1995 and October 1996. Induction began with one cycle of conventional chemotherapy followed by six sequential cycles of high‐dose chemotherapy comprising two cycles of etoposide 800 mg/m2/day over 3 days, two cycles of cyclophosphamide 2,000 mg/m2/day over 3 days, and two cycles of carboplatin 400 mg/m2/day over 5 days, followed by stem cell rescue.
Results
Thirteen patients (13/20) received this induction with acceptable toxicity and adequate stem cell harvest. Of these, nine (9/13) underwent surgery according to the protocol, while one patient was given a consolidation regimen prior to surgery. No toxic death was recorded. At the end of induction, complete remission was achieved in 10 cases (50%), with six still alive in July 2009. The 5‐year event‐free survival and OS were 35 ± 11% and 40 ± 11%, respectively.
Conclusion
NB96 therapy is feasible and tolerated without lethal toxicity. Nevertheless, given the small sample size and absence of randomization in our study, the effectiveness of this strategy based on metastasis complete response rates and long‐term outcome was not superior to other intensive chemotherapy regimens. Pediatr Blood Cancer 2011; 57: 965–971. © 2011 Wiley‐Liss, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>ISSN: 1545-5017</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.23232</identifier><identifier>PMID: 21744481</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Child, Preschool ; clinical trials ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; myeloablative therapy ; neuroblastoma ; Neuroblastoma - diagnosis ; Neuroblastoma - therapy ; Pilot Projects ; Stem Cell Transplantation - adverse effects ; Survival Analysis ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Pediatric blood & cancer, 2011-12, Vol.57 (6), p.965-971</ispartof><rights>Copyright © 2011 Wiley‐Liss, Inc.</rights><rights>Copyright © 2011 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713</citedby><cites>FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21744481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Monnereau-Laborde, Sylvie</creatorcontrib><creatorcontrib>Munzer, Caroline</creatorcontrib><creatorcontrib>Valteau-Couanet, Dominique</creatorcontrib><creatorcontrib>Ansoborlo, Sophie</creatorcontrib><creatorcontrib>Coze, Carole</creatorcontrib><creatorcontrib>Chastagner, Pascal</creatorcontrib><creatorcontrib>Rubie, Hervé</creatorcontrib><creatorcontrib>Demeocq, François</creatorcontrib><creatorcontrib>Stephan, Jean-Louis</creatorcontrib><creatorcontrib>Hartmann, Olivier</creatorcontrib><creatorcontrib>Perel, Yves</creatorcontrib><title>A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age</title><title>Pediatric blood & cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>Background
To improve outcome and overall survival (OS) in high‐risk neuroblastoma, NB96 induction therapy was intensified using sequential high‐dose chemotherapy and autologous stem cell rescue.
Procedure
Twenty children were included in this pilot study undertaken at seven reference centers in France, between May 1995 and October 1996. Induction began with one cycle of conventional chemotherapy followed by six sequential cycles of high‐dose chemotherapy comprising two cycles of etoposide 800 mg/m2/day over 3 days, two cycles of cyclophosphamide 2,000 mg/m2/day over 3 days, and two cycles of carboplatin 400 mg/m2/day over 5 days, followed by stem cell rescue.
Results
Thirteen patients (13/20) received this induction with acceptable toxicity and adequate stem cell harvest. Of these, nine (9/13) underwent surgery according to the protocol, while one patient was given a consolidation regimen prior to surgery. No toxic death was recorded. At the end of induction, complete remission was achieved in 10 cases (50%), with six still alive in July 2009. The 5‐year event‐free survival and OS were 35 ± 11% and 40 ± 11%, respectively.
Conclusion
NB96 therapy is feasible and tolerated without lethal toxicity. Nevertheless, given the small sample size and absence of randomization in our study, the effectiveness of this strategy based on metastasis complete response rates and long‐term outcome was not superior to other intensive chemotherapy regimens. Pediatr Blood Cancer 2011; 57: 965–971. © 2011 Wiley‐Liss, Inc.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>clinical trials</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>myeloablative therapy</subject><subject>neuroblastoma</subject><subject>Neuroblastoma - diagnosis</subject><subject>Neuroblastoma - therapy</subject><subject>Pilot Projects</subject><subject>Stem Cell Transplantation - adverse effects</subject><subject>Survival Analysis</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>1545-5009</issn><issn>1545-5017</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhiMEoqVw4AWQj-0hbRzbsXNsF1iQqsKhFG6WY082pokd7KSwvBVviJd094bm4JH8zSfN_Fn2GhfnuCjKi7HR5yVJ9SQ7xoyynBWYPz30RX2UvYjxe0Krgonn2VGJOaVU4OPszyUyPkJu3QQu2gdAahyDV7pDpzdXdXWGWh-QdWbWk_UOTR0ENW7RPNne_rZugyL8mMFNVvWos5su3-mQ7mDwe1Y5g-IEA9LQ9yhA1DMk5YIHG--Rgzn4pldx8oPafenO9iaAQ_4BAsJoCyog3yK1gZfZs1b1EV49vifZl_fvblcf8utP64-ry-tck5qVeQulogqgEaLERhBaVoK2AtdNbbhuoOC1IDUF0QIWDSdG0bYyQjQtI4ZzTE6y08WbzpE2jJMcbNxtoBz4OUpMKk5FyWqS0LMF1cHHGKCVY7CDCluJC7lLSKaE5L-EEvvmUTs3A5gDuY8kARcL8NP2sP2_SX6-Wu2V-TJh05V_HSZUuJcVJ5zJrzdrecdu19_eiju5In8BCyOsdA</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Monnereau-Laborde, Sylvie</creator><creator>Munzer, Caroline</creator><creator>Valteau-Couanet, Dominique</creator><creator>Ansoborlo, Sophie</creator><creator>Coze, Carole</creator><creator>Chastagner, Pascal</creator><creator>Rubie, Hervé</creator><creator>Demeocq, François</creator><creator>Stephan, Jean-Louis</creator><creator>Hartmann, Olivier</creator><creator>Perel, Yves</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20111201</creationdate><title>A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age</title><author>Monnereau-Laborde, Sylvie ; Munzer, Caroline ; Valteau-Couanet, Dominique ; Ansoborlo, Sophie ; Coze, Carole ; Chastagner, Pascal ; Rubie, Hervé ; Demeocq, François ; Stephan, Jean-Louis ; Hartmann, Olivier ; Perel, Yves</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>clinical trials</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>myeloablative therapy</topic><topic>neuroblastoma</topic><topic>Neuroblastoma - diagnosis</topic><topic>Neuroblastoma - therapy</topic><topic>Pilot Projects</topic><topic>Stem Cell Transplantation - adverse effects</topic><topic>Survival Analysis</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Monnereau-Laborde, Sylvie</creatorcontrib><creatorcontrib>Munzer, Caroline</creatorcontrib><creatorcontrib>Valteau-Couanet, Dominique</creatorcontrib><creatorcontrib>Ansoborlo, Sophie</creatorcontrib><creatorcontrib>Coze, Carole</creatorcontrib><creatorcontrib>Chastagner, Pascal</creatorcontrib><creatorcontrib>Rubie, Hervé</creatorcontrib><creatorcontrib>Demeocq, François</creatorcontrib><creatorcontrib>Stephan, Jean-Louis</creatorcontrib><creatorcontrib>Hartmann, Olivier</creatorcontrib><creatorcontrib>Perel, Yves</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Monnereau-Laborde, Sylvie</au><au>Munzer, Caroline</au><au>Valteau-Couanet, Dominique</au><au>Ansoborlo, Sophie</au><au>Coze, Carole</au><au>Chastagner, Pascal</au><au>Rubie, Hervé</au><au>Demeocq, François</au><au>Stephan, Jean-Louis</au><au>Hartmann, Olivier</au><au>Perel, Yves</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>57</volume><issue>6</issue><spage>965</spage><epage>971</epage><pages>965-971</pages><issn>1545-5009</issn><issn>1545-5017</issn><eissn>1545-5017</eissn><abstract>Background
To improve outcome and overall survival (OS) in high‐risk neuroblastoma, NB96 induction therapy was intensified using sequential high‐dose chemotherapy and autologous stem cell rescue.
Procedure
Twenty children were included in this pilot study undertaken at seven reference centers in France, between May 1995 and October 1996. Induction began with one cycle of conventional chemotherapy followed by six sequential cycles of high‐dose chemotherapy comprising two cycles of etoposide 800 mg/m2/day over 3 days, two cycles of cyclophosphamide 2,000 mg/m2/day over 3 days, and two cycles of carboplatin 400 mg/m2/day over 5 days, followed by stem cell rescue.
Results
Thirteen patients (13/20) received this induction with acceptable toxicity and adequate stem cell harvest. Of these, nine (9/13) underwent surgery according to the protocol, while one patient was given a consolidation regimen prior to surgery. No toxic death was recorded. At the end of induction, complete remission was achieved in 10 cases (50%), with six still alive in July 2009. The 5‐year event‐free survival and OS were 35 ± 11% and 40 ± 11%, respectively.
Conclusion
NB96 therapy is feasible and tolerated without lethal toxicity. Nevertheless, given the small sample size and absence of randomization in our study, the effectiveness of this strategy based on metastasis complete response rates and long‐term outcome was not superior to other intensive chemotherapy regimens. Pediatr Blood Cancer 2011; 57: 965–971. © 2011 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21744481</pmid><doi>10.1002/pbc.23232</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1545-5009 |
ispartof | Pediatric blood & cancer, 2011-12, Vol.57 (6), p.965-971 |
issn | 1545-5009 1545-5017 1545-5017 |
language | eng |
recordid | cdi_proquest_miscellaneous_1367482593 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child Child, Preschool clinical trials Dose-Response Relationship, Drug Female Follow-Up Studies Humans Infant Male myeloablative therapy neuroblastoma Neuroblastoma - diagnosis Neuroblastoma - therapy Pilot Projects Stem Cell Transplantation - adverse effects Survival Analysis Transplantation, Autologous Treatment Outcome |
title | A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T09%3A20%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20dose-intensive%20approach%20(NB96)%20for%20induction%20therapy%20utilizing%20sequential%20high-dose%20chemotherapy%20and%20stem%20cell%20rescue%20in%20high-risk%20neuroblastoma%20in%20children%20over%201%20year%20of%20age&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Monnereau-Laborde,%20Sylvie&rft.date=2011-12-01&rft.volume=57&rft.issue=6&rft.spage=965&rft.epage=971&rft.pages=965-971&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.23232&rft_dat=%3Cproquest_cross%3E1367482593%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3952-fe2a4aeeb8821d8342684f819b9d7cbe0798394e8fe18b73da4f6d88bf53d7713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1367482593&rft_id=info:pmid/21744481&rfr_iscdi=true |